Telomir Pharmaceuticals (TELO) Enterprise Value (2022 - 2026)
Telomir Pharmaceuticals (TELO) posted Enterprise Value of -$7.3 million for Q4 2025, little changed sequentially from -$7.3 million in Q3 2025, and down 475.51% YoY from $1.9 million in Q4 2024.
Telomir Pharmaceuticals (TELO) Enterprise Value (2022 - 2026) Analysis & Trends
Telomir Pharmaceuticals has reported Enterprise Value for 4 years, with the latest figure at -$7.3 million in Q4 2025.
- Quarterly Enterprise Value fell 475.51% year-over-year to -$7.3 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$7.3 million (down 475.51% YoY) and the FY2025 annual result came in at -$7.3 million, down 475.51% from the prior year.
- Enterprise Value steadied at -$7.3 million in Q4 2025 per TELO's latest filing, from -$7.3 million in the prior quarter.
- Over five years, Enterprise Value peaked at -$1231.0 in Q4 2023 and troughed at -$7.3 million in Q3 2025.
- A 4-year average of -$1.8 million and a median of -$754323.0 in 2025 frame the typical range for Enterprise Value.
- The sharpest annual moves came in 2024 and 2025: Enterprise Value tumbled 182523.13% in 2024, then jumped 87.79% in 2025.
- Over 4 years, Enterprise Value stood at -$1419.0 in 2022, then gained by 13.25% to -$1231.0 in 2023, then plunged by 102753.86% to -$1.3 million in 2024, then sank by 475.51% to -$7.3 million in 2025.
- According to Business Quant data, Enterprise Value over the past three periods registered -$7.3 million, -$7.3 million, and -$754323.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | -5.18 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -5.14 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | -5.10 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -3.31 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -18.39 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -1.16 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 2.12 Bn |
| 10 | Telomir Pharmaceuticals | 69.05 Mn | 69.05 Mn | - | -5.20 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -5.20 Mn |
| Dec 31, 2025 | -7.29 Mn |
| Sep 30, 2025 | -7.30 Mn |
| Jun 30, 2025 | -754,323.00 |
| Mar 31, 2025 | -402,999.00 |
| Dec 31, 2024 | -1.27 Mn |
| Sep 30, 2024 | -834,638.00 |
| Jun 30, 2024 | -1.88 Mn |
| Mar 31, 2024 | -3.30 Mn |
| Dec 31, 2023 | -1,231.00 |
| Sep 30, 2023 | -2,452.00 |
| Jun 30, 2023 | -14,629.00 |
| Mar 31, 2023 | -1,807.00 |
| Dec 31, 2022 | -1,419.00 |